<DOC>
	<DOCNO>NCT00514761</DOCNO>
	<brief_summary>The purpose study assess benefit use AZD6244 treatment metastatic colorectal cancer comparison another treatment call capecitabine . This study also assess safe well tolerate AZD6244 .</brief_summary>
	<brief_title>Phase II Efficacy Study AZD6244 Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>colorectal cancer require treatment fail one two previous chemotherapeutic regimen must include oxaliplatin and/or irinotecan World Health Organisation ( WHO ) performance status 02 life expectancy &gt; 12 week previous therapy EGFR inhibitor , MEK inhibitor capecitabine recent surgery , unhealed surgical incision severe concomitant condition make undesirable patient participate study nausea vomiting , chronic gastrointestinal disease significant bowel resection would preclude adequate absorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>AZD6244</keyword>
</DOC>